uniQure N.V. Revenue from Related Parties
uniQure N.V. (QURE) reported Revenue from Related Parties of $4.12 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-14.
Discontinued › Income Statement › Other Income
us-gaap:RevenueFromRelatedParties · last filed 2018-03-14
- uniQure N.V. revenue from related parties for the quarter ending 2017-12-31 was $1.06M, a 10.18% increase year-over-year.
- uniQure N.V. revenue from related parties for the quarter ending 2017-09-30 was $1.12M, a 13.19% increase year-over-year.
- uniQure N.V. revenue from related parties for the quarter ending 2016-12-31 was $963.00K.
- uniQure N.V. revenue from related parties for the quarter ending 2016-09-30 was $993.00K.
- uniQure N.V. revenue from related parties for fiscal 2017 was $4.12M, a 4.59% increase from fiscal 2016.
- uniQure N.V. revenue from related parties for fiscal 2016 was $3.94M, a 18.14% increase from fiscal 2015.
- uniQure N.V. revenue from related parties for fiscal 2015 was $3.33M.
| Period end | Revenue from Related Parties 3 month | Revenue from Related Parties 6 month | Revenue from Related Parties 9 month | Revenue from Related Parties 12 month |
|---|---|---|---|---|
| 2017-12-31 | $1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $2.19M derived: sum of 2 quarters · filed 2018-03-14 | $4.12M 10-K · filed 2018-03-14 | |
| 2017-09-30 | $1.12M 10-Q · filed 2017-11-01 | $3.06M 10-Q · filed 2017-11-01 | ||
| 2016-12-31 | $963.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $1.96M derived: sum of 2 quarters · filed 2018-03-14 | $3.94M 10-K · filed 2018-03-14 | |
| 2016-09-30 | $993.00K 10-Q · filed 2017-11-01 | $2.98M 10-Q · filed 2017-11-01 | ||
| 2015-12-31 | $3.33M 10-K · filed 2018-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |